OncoMatch/Clinical Trials/NCT04532606
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Is NCT04532606 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Remimazolam and Propofol for benzodiazepines.
Treatment: Remimazolam · Propofol — Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Performance status
ASA 0–3
Demographics
Prior therapy
Cannot have received: benzodiazepine
Use of benzodiazepines for 1 week within the last month before surgery
Lab requirements
Kidney function
severe renal dysfunction (undergoing dialysis before surgery) [excluded]
Liver function
severe hepatic dysfunction (Child-Pugh class C) [excluded]
severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04532606 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior benzodiazepine disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 50 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages